Linde PLC vs Sana Biotechnology Inc — how do they compare? Linde PLC trades at $506.33 (market cap $236.74B), while Sana Biotechnology Inc trades at $3.2 (market cap $873.84M). The key difference: Linde PLC is far larger — about 270.9× Sana Biotechnology Inc's market cap, and Linde PLC pays a 1.25% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| LIN | SANA | |
|---|---|---|
Market Cap | $236.74B | $873.84M |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $5.92 |
52-Week Low | $389.38 | $2.68 |
Enterprise Value | $259.10B | $848.03M |
Dividend Yield | 1.25% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Trailing returns across standard periods
Latest headlines on both assets
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →